Clinical trials
HIV 2 Infection clinical trials
Below are recruiting hiv 2 infection clinical trials, each written for real people, not researchers. We’re tracking 139 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05633056Recruiting
Testing TB medicines for people with drug-resistant TB and HIV
This trial studies a treatment plan for people who have both drug-resistant tuberculosis (TB) and HIV. It focuses on starting a specific TB medication (bedaquiline) and, if needed, HIV treatment soon after enrollment to see what approach works best.
Durban, KwaZulu-NatalAges 18 years+ - NCT05418868RecruitingPhase 1
Long-acting cabotegravir injection safety in healthy adults
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
Orlando, FloridaAges 18–55 - NCT04984772Enrolling by invitation
HIV and hepatitis B coinfection follow-up study in Europe
This study follows people who have both HIV and hepatitis B over time to better understand how the infection responds after starting treatment. Your information (and sometimes stored blood samples) helps researchers track changes from the start of therapy to about 2 years later.
Ages 16 years+ - NCT04499053RecruitingPhase 2
Durvalumab and tremelimumab with chemotherapy for advanced lung cancer in HIV
This trial tests a combination of immune therapy drugs (durvalumab and tremelimumab) given with chemotherapy in people with stage IV non-small cell lung cancer who also have HIV. It may help shrink or control cancer by boosting the immune response while keeping HIV well controlled.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04052022Recruiting
Study of TB flare-ups in people without HIV
This study looks at why some people with tuberculosis (TB) get worse or develop new inflammation after they initially start improving on treatment—called a “paradoxical reaction.” It collects blood and tissue samples to better understand these flare-ups and guide future care.
Bethesda, MarylandAges 18–99 - NCT00187512Recruiting
Study of how HIV treatment changes outcomes over time
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
San Francisco, CaliforniaAges 18 years+ - NCT05985642Recruiting
HIV treatment interruption study for long-term participants
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
San Francisco, CaliforniaAges 18 years+ - NCT06749054RecruitingPhase 2
Long-acting HIV treatment for teens and children with drug resistance
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
Atlanta, GeorgiaAges Up to 17 years - NCT05660980RecruitingPhase 1/Phase 2
Oral and monthly shots for HIV control in children
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
Atlanta, GeorgiaAges 2–11 - NCT07266831RecruitingPhase 2/Phase 3
New HIV treatment for people not yet on medication
This study tests a new combination medicine for people with HIV who have never taken treatment. It aims to see if it is safe and helps reduce the amount of virus in the blood.
Los Angeles, CaliforniaAges 18 years+ - NCT07711223RecruitingPhase 1/Phase 2
New HIV pill compared to standard treatment for untreated adults
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
BeijingAges 18 years+ - NCT06691321Recruiting
Caspofungin for Pneumocystis Pneumonia in HIV patients
This trial tests caspofungin, a medicine, for treating Pneumocystis pneumonia (PCP) in people living with HIV. It aims to see if it works better than standard treatments.
Mexico City, TlalpanAges 18–60 - NCT07616739RecruitingPhase 4
Dolutegravir and Lamivudine for Pregnant Women with HIV
This study tests a two-drug HIV treatment combination (dolutegravir and lamivudine) for pregnant women who have never taken HIV medicine before. The goal is to see if this combination safely controls HIV during pregnancy and protects the baby.
Ciudad Autónoma de Buenos Aires, Buenos AiresAges 15 years+ - NCT07596888RecruitingPhase 1
Early safety study of experimental HIV treatment IAP-086-1
This is an early-stage trial testing a new experimental drug (IAP-086-1) in people with HIV who have their virus well-controlled on current medications. Researchers want to understand how safe the drug is and how the body handles it.
Chapel Hill, North CarolinaAges 18–70 - NCT07357584RecruitingPhase 4
Quick-start HIV treatment with doravirine for newly diagnosed adults
This study tests a fast-start HIV treatment using doravirine, tenofovir, and lamivudine for people who were just diagnosed with HIV in the last 30 days and have never taken HIV medications before. The goal is to see if starting treatment right away is safe and effective.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 18–90 - NCT07308782RecruitingPhase 2
Testing a new HIV treatment in people not yet on therapy
This trial is testing an experimental HIV pill called CL-197. It's for people with HIV who have never taken any HIV medicines before. The study lasts about 2 weeks and aims to see how the drug works in the body.
BeijingAges 18–60 - NCT07181486RecruitingPhase 1
Safety study of a vaginal gel for healthy women
This trial tests a gel placed in the vagina to see if it is safe. Healthy women with regular periods who have a steady partner may join.
San Francisco, CaliforniaAges 18–45 - NCT07030075Recruiting
Flu and respiratory infection study in Lusaka
This study looks at flu-like symptoms and other respiratory infections in adults in Lusaka, Zambia. It aims to understand how these infections affect people with and without HIV, and may help improve care.
Lusaka, Lusaka ProvinceAges 18 years+ - NCT06774872RecruitingPhase 2
Comparing two-drug HIV maintenance treatments
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
Paris, Île-de-France RegionAges 18 years+ - NCT06843902RecruitingPhase 2
Improving heart blood flow in women with HIV and diabetes or kidney problems
This trial tests a new approach to improve blood flow in the hearts of women with HIV who also have diabetes or kidney problems. It might help prevent heart disease in this population.
Boston, MassachusettsAges 45–75 - NCT05136703Recruiting
Study depression treatment effects in people living with HIV
This study looks at how depression and its treatment may affect the brain and immune-related body systems in people with HIV. You may be eligible if you have depression and a well-controlled HIV viral load, and you can safely complete brain MRI scans.
Coral Gables, FloridaAges 18 years+ - NCT05300035RecruitingPhase 2
HIV treatment add-on antibodies during early infection
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
BobignyAges 18–70 - NCT04057924Recruiting
Watchful waiting for certain abnormal cells in the cervix
This trial checks whether “therapy abstention” (not treating right away) and close monitoring is safe for certain high-grade cervical cell changes. It may help some people avoid immediate procedures while still catching any progression early.
BordeauxAges 18 years+ - NCT06684379RecruitingPhase 1/Phase 2
Two Doses of PRS CK STORM for Severe Viral Pneumonia
This study tests a new drug called PRS CK STORM to see if it can safely calm the body's overactive immune response (cytokine storm) in people with severe pneumonia from COVID-19, flu, or RSV who need oxygen. It aims to reduce inflammation and improve recovery.
Alcalá de Henares, MadridAges 18 years+
Hear when a new HIV 2 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv 2 infection?
- Yes. Clin2 currently lists 139 recruiting hiv 2 infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv 2 infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv 2 infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.